About Us

Silence Therapeutics is developing a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need.

Our proprietary technology can be used to engineer short interfering ribonucleic acids (siRNAs) that bind specifically to and silence, through the RNAi pathway, almost any gene in the human genome to which siRNA can be delivered. Using our RNAi-directed platform technologies, we have generated siRNA product candidates both for our internal development pipeline as well as for out-licensed programs with third-party collaborators. We are currently
focused on developing siRNA molecules for the potential treatment of cardiovascular disease, rare diseases such as iron loading anemias, and complement-mediated disorders.


Our strategy is to develop RNAi-based therapeutics to tackle life-threatening diseases. We strive to do this in a risk-diversified manner to maximise our probability of success.

StrategyBullets_LeftHandColumn[1].png StrategyBullets_RightHandColumn.png (2)

Our People

Well equipped to drive execution

Mark Rother photo (trimmed).PNG

Management Team

Our management team is highly experienced in a variety of relevant sectors, from molecular biology and genetics to finance and investment banking. This combination of skillsets enables the team to effectively execute our business plan.

Strong leadership

Iain Ross 2.PNG

Board of Directors

Our Board provides oversight to ensure that the highest Corporate Governance standards are maintained, applies internal financial controls and approves the Company’s policy and strategy.

Access to distinguished experts and KOLs


Scientific Advisory Board

We aim to stay in the frontline of the fast-moving field of oligonucleotide therapeutics. Our Scientific Advisory Board (SAB) is a group of world-leading experts in drug discovery and clinical development with particular expertise in the rare disease space. The SAB challenges us to excel at siRNA molecular design, drug discovery, and development

Corporate responsibility

Silence strives to conduct its business in an ethical, responsible and transparent manner. We set high standards of conduct and behaviour and expect all our employees, officers and directors to adhere to those standards. Partners, employees, customers and suppliers can all expect the highest standards of professional conduct when dealing with our Company. The Board of Directors is responsible for setting and reviewing the Company’s values and standards.

Silence recognises and accepts its responsibility as an employer to maintain, as far as is reasonably practicable, the safety and health of its employees and of other persons who may be affected by its activities. Silence Therapeutics is an equal opportunities employer.



Our mission is to continue to build Silence as a global leader in the field of RNAi therapeutics, where our technology can create a new generation of approaches to address unmet medical need and improve outcomes for patients.

If you are a passionate individual with relevant experience, and a desire to subscribe to our goals, we would be delighted to hear from you.